DOCSLIB.ORG

1566 Cough Suppressants Expectorants Mucolytics and Nasal Decongestants

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1566 Cough Suppressants Expectorants Mucolytics and Nasal Decongestants 1566 Cough Suppressants Expectorants Mucolytics and Nasal Decongestants Naphoptic-A; Ocuhist; Opcon-A; VasoClear A; VasoClear†; Vasocon-A; Vi- Profile Noscapine Hydrochloride (BANM, rINNM) sine-A; Venez.: Camolyn Plus; Fesanol†; Pinazo; Soltin; Soluclear. Nicocodine is an opioid related to codeine (p.37). It has been Used as an adjunct in: Fr.: Xylocaine; Spain: Anestesico. used as the hydrochloride for its central cough suppressant ef- Hidrocloruro de noscapina; Narcotine Hydrochloride; Noscap- fects in non-productive cough (p.1547). Nicocodine hydrochlo- ine, chlorhydrate de; Noscapini hydrochloridum; Noscapini Hy- ride is given orally in doses of 5 to 7.5 mg up to three times daily. drochloridum Monohydricum; Noscapinium Chloride; Noskapi- inihydrokloridi; Noskapin hydrochlorid monohydrát; Noskapin- Neltenexine (rINN) Preparations hydroklorid; Noskapino hidrochloridas; Noskapiny chlorowo- Neltenexina; Nelténexine; Neltenexinum. 4′,6′-Dibromo-α- Proprietary Preparations (details are given in Part 3) dorek; Noszkapin-hidroklorid. [(trans-4-hydroxycyclohexyl)amino]-2-thiophene-carboxy-o- Austria: Tusscodin. toluidide. Носкапина Гидрохлорид Нелтенексин C22H23NO7,HCl,H2O = 467.9. CAS — 912-60-7 (anhydrous noscapine hydrochloride). C18H20Br2N2O2S = 488.2. Normethadone Hydrochloride (BANM, rINNM) CAS — 99453-84-6. ATC — R05DA07. ATC — R05CB14. Desmethylmethadone Hydrochloride; Hidrocloruro de ATC Vet — QR05DA07. normetadona; Hoechst-10582 (normethadone); Normétha- ATC Vet — QR05CB14. Pharmacopoeias. In Eur. (see p.vii) and Int. (both with H O); done, Chlorhydrate de; Normethadoni Hydrochloridum; Phe- 2 in Jpn (with xH2O). nyldimazone Hydrochloride. 6-Dimethylamino-4,4-diphenylhex- Ph. Eur. 6.2 (Noscapine Hydrochloride). A white or almost Br an-3-one hydrochloride. white, hygroscopic, crystalline powder or colourless crystals. Норметадона Гидрохлорид Freely soluble in water and in alcohol. Aqueous solutions are C20H25NO,HCl = 331.9. faintly acid; the base may be precipitated when the solutions are Br CAS — 467-85-6 (normethadone); 847-84-7 (normetha- allowed to stand. A 2% solution in water has a pH of not less than done hydrochloride). 3.0. Protect from light. ATC — R05DA06. HN NH Adverse Effects and Precautions ATC Vet — QR05DA06. As for Dextromethorphan, p.1555. Hypersensitivity reactions O H OH have been reported. S CH3 Breast feeding. Maximum concentrations of noscapine in the H breast milk of 8 women given 100 or 150 mg of noscapine N ranged1 from 11 to 83 nanograms/mL. It was estimated that CH3 breast-fed infants of mothers receiving noscapine 50 mg three Profile times daily would ingest at most 300 nanograms/kg of noscap- Neltenexine is a mucolytic that has been used in respiratory dis- CH3 ine, an amount considered unlikely to be a hazard. No adverse orders associated with productive cough (p.1547). It has been O effects have been seen in breast-fed infants whose mothers were given orally as the monohydrate, in usual doses of 37.4 mg three given noscapine, and the American Academy of Pediatrics2 con- siders that it is therefore usually compatible with breast feeding. times daily. Neltenexine has also been given rectally as the hy- (normethadone) drochloride. 1. Olsson B, et al. Excretion of noscapine in human breast milk. Preparations Eur J Clin Pharmacol 1986; 30: 213–15. Profile 2. American Academy of Pediatrics. The transfer of drugs and oth- Proprietary Preparations (details are given in Part 3) Normethadone is closely related to methadone (p.82). The hy- er chemicals into human milk. Pediatrics 2001; 108: 776–89. Ital.: Alveoten; Muco4; Tenoxol. drochloride is given orally as a cough suppressant in preparations Correction. ibid.; 1029. Also available at: for non-productive cough. http://aappolicy.aappublications.org/cgi/content/full/ pediatrics%3b108/3/776 (accessed 13/12/06) Preparations Nepinalone (rINN) Pregnancy. The UK CSM stood by their recommendation1 that Proprietary Preparations (details are given in Part 3) Nepinalona; Népinalone; Nepinalonum. (±)-3,4-Dihydro-1-me- products containing noscapine should be contra-indicated in Multi-ingredient: Canad.: Cophylac. women of child-bearing potential (because of potential mutagen- thyl-1-(2-piperidinoethyl)-2(1H)-napthalenone. ic effects2), after criticism that the decision was based solely on Непиналон the results of in-vitro work.3 C H NO = 271.4. 18 25 Noscapine (BAN, rINN) 1. Asscher AW, Fowler LK. Papaveretum in women of childbear- CAS — 22443-11-4. ing potential. BMJ 1991; 303: 648. ATC — R05DB26. Narcotine; L-α-Narcotine; Noscapina; Noscapinum; Noskapiini; 2. Committee on Safety of Medicines. Genotoxicity of papaveretum ATC Vet — QR05DB26. Noskapin; Noskapinas; Noszkapin; NSC-5366. (3S)-6,7-Dimeth- and noscapine. Current Problems 31 1991. Also available at: http:// oxy-3-[(5R)-5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxo- www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE& dDocName=CON2024449&RevisionSelectionMethod= lo[4,5-g]isoquinolin-5-yl]phthalide. LatestReleased (accessed 21/03/07) Носкапин 3. Allen S, et al. Papaveretum in women of child bearing potential. BMJ 1991; 303: 647. C22H23NO7 = 413.4. N CAS — 128-62-1. Interactions ATC — R05DA07. Noscapine should not be given with alcohol or other CNS de- ATC Vet — QR05DA07. pressants. CH3 O Anticoagulants. For mention of a possible interaction between O noscapine and warfarin, see Cough Suppressants, p.1430. Pharmacokinetics N O ◊ References. CH3 Profile H H 1. Karlsson MO, et al. Pharmacokinetics of oral noscapine. Eur J Nepinalone has been used as the hydrochloride as a cough sup- H3CO Clin Pharmacol 1990; 39: 275–9. pressant in non-productive cough (p.1547). Oral doses of nepi- O 2. Karlsson MO, Dahlstrom B. Serum protein binding of noscap- ine: influence of a reversible hydrolysis. J Pharm Pharmacol nalone hydrochloride 10 mg have been given three times daily. 1990; 42: 140–3. Preparations O Uses and Administration Proprietary Preparations (details are given in Part 3) H3CO OCH Noscapine is a centrally acting cough suppressant that has ac- Ital.: Nepituss; Placatus; Tussolvina. 3 tions and uses similar to those of dextromethorphan (p.1556). It is given in an oral dose of up to 50 mg three times daily. It is also Description. Noscapine is an alkaloid obtained from opium. used rectally. Noscapine has also been given as the ascorbate, Nicocodine (BAN, rINN) Pharmacopoeias. In Chin., Eur. (see p.vii), Int., Jpn, and US. camsilate, embonate, and the hydrochloride. Ph. Eur. 6.2 (Noscapine). A white or almost white, crystalline Nicocodina; Nicocodinum. 6-Nicotinoylcodeine; 3-O-Methyl-6- powder or colourless crystals. Practically insoluble in water at Preparations O-nicotinoylmorphine. 20°, very slightly soluble at 100°; slightly soluble in alcohol; sol- Proprietary Preparations (details are given in Part 3) Никокодин uble in acetone; dissolves in strong acids although the base may Belg.: Nosca-Mereprine; Noscaflex; Chile: Factoss†; Ger.: Capval; Hong Kong: Recoma; Indon.: Longatin; Mercotin; Neth.: Roter Noscapect; C24H24N2O4 = 404.5. be precipitated on dilution with water. Protect from light. CAS — 3688-66-2. Streptuss kriebelhoest†; S.Afr.: Nitepax; Spain: Tuscalman; Swed.: Nipax- USP 31 (Noscapine). A fine, white or practically white, crystal- on; Switz.: Tussanil N. line powder. Practically insoluble in water; slightly soluble in al- Multi-ingredient: Arg.: Funciobron; Graneodin N; Jarabe Bago†; No-Tos cohol and in ether; soluble in acetone; freely soluble in chloro- Pocket; Saltos Infantil†; Saltos†; Tosedrin Compuesto; Vi-Balsabron†; Aus- O form. tria: Pneumopect; Tuscalman; Belg.: Noscaflex; Rosils†; Braz.: Expec- H3C tussin†; Ipecol†; Chile: AB Antitusivo; Captus; Congestex; Cotibin Flu†; Freshmel Tos; Graneodin N†; Graneodin-Tos; Gripexin Limonada Caliente; Noscapine Camsilate (BANM, rINNM) Gripexin Nueva Formula Compuesto†; Kitadol Flu Noche†; Kitadol Flu†; Pectoserum†; Tapsin Compuesto; Tapsin Compuesto con Clorfenamina; O Camphoscapine; Camsilato de noscapina; Noscapine, Camsilate de; Noscapine Camsylate; Noscapini Camsilas. Noscapine cam- Tapsin Compuesto Dia/Noche Plus; Tapsin Compuesto DN; Tapsin H Limonada D.N.†; Tapsin Limonada Dia†; Tapsin Limonada Noche†; Fin.: O N phor-10-sulphonate. Codesan N†; Posivil†; Fr.: Tussisedal; Hong Kong: Asmeton; Coldcap-A; H H Носкапина Камзилат Coldrex†; Coldtab-2; Mefedra-N†; Panadol Cold & Flu Extra; India: Co- CH3 scopin; Coscopin Plus; Indon.: Flunadin; Noscapax; Paratusin; Tilomix; N O C22H23NO7, C10H16O4S = 645.7. Swed.: Spasmofen; Switz.: Brosoline-Rectocaps†; DemoTussil; Hederix; CAS — 25333-79-3. Noscorex; Spasmosol; Tossamine; Tossamine plus; Tuscalman; Tussanil ATC — R05DA07. Compositum†; Thai.: Asmeton†; Turk.: Coldeks. ATC Vet — QR05DA07..
Load more

Recommended publications
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • UNIVERSITE DE NANTES Thomas Gelineau
    UNIVERSITE DE NANTES __________ FACULTE DE MEDECINE __________ Année 2011 N° 139 THESE pour le DIPLÔME D’ÉTAT DE DOCTEUR EN MÉDECINE DES de médecine générale par Thomas Gelineau né le 29 janvier 1983 à Cholet __________ Présentée et soutenue publiquement le 06/12/2011 __________ LE RHUME DE L'ENFANT ET SON TRAITEMENT: DECISION PARTAGEE AVEC LES PARENTS D'APRES UN QUESTIONNAIRE __________ Président : Monsieur le Professeur Olivier MALARD Directeur de thèse : Madame le Professeur Jacqueline LACAILLE 1 Table des matières IIntroduction................................................................................................................ 7 IIDéfinition, état des connaissances...........................................................................8 1Le rhume.......................................................................................................................................8 APhysiopathologie............................................................................................................................. 8 aL'origine virale.................................................................................................................................... 8 bLa saisonnalité................................................................................................................................... 8 cL'âge de survenue.............................................................................................................................. 9 dLe sexe..................................................................................................................................................
    [Show full text]
  • Use of Antitussives After the Initiation of Angiotensin-Converting Enzyme Inhibitors
    저작자표시-비영리-변경금지 2.0 대한민국 이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게 l 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다. 다음과 같은 조건을 따라야 합니다: 저작자표시. 귀하는 원저작자를 표시하여야 합니다. 비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다. 변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다. l 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건 을 명확하게 나타내어야 합니다. l 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다. 저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다. 이것은 이용허락규약(Legal Code)을 이해하기 쉽게 요약한 것입니다. Disclaimer 약학 석사학위 논문 안지오텐신 전환 효소 억제제 개시 이후 진해제의 사용 분석 Use of Antitussives After the Initiation of Angiotensin-Converting Enzyme Inhibitors 2017년 8월 서울대학교 대학원 약학과 사회약학전공 권 익 태 안지오텐신 전환 효소 억제제 개시 이후 진해제의 사용 분석 Use of Antitussives After the Initiation of Angiotensin-Converting Enzyme Inhibitors 지도교수 홍 송 희 이 논문을 권익태 석사학위논문으로 제출함 2017년 4월 서울대학교 대학원 약학과 사회약학전공 권 익 태 권익태의 석사학위논문을 인준함 2017년 6월 위 원 장 (인) 부 위 원 장 (인) 위 원 (인) Abstract Use of Antitussives After the Initiation of Angiotensin-Converting Enzyme Inhibitors Ik Tae Kwon Department of Social Pharmacy College of Pharmacy, Seoul National University Background Angiotensin-converting enzyme inhibitors (ACEI) can induce a dry cough, more frequently among Asians. If healthcare professionals fail to detect coughs induced by an ACEI, patients are at risk of getting antitussives inappropriately instead of discontinuing ACEI. The purpose of this study was to examine how the initiation of ACEI affects the likelihood of antitussive uses compared with the initiation of Angiotensin Receptor Blocker (ARB) and to determine the effect of the antitussive use on the duration and adherence of therapy in a Korean population.
    [Show full text]
  • General Pharmacology
    GENERAL PHARMACOLOGY Winners of “Nobel” prize for their contribution to pharmacology Year Name Contribution 1923 Frederick Banting Discovery of insulin John McLeod 1939 Gerhard Domagk Discovery of antibacterial effects of prontosil 1945 Sir Alexander Fleming Discovery of penicillin & its purification Ernst Boris Chain Sir Howard Walter Florey 1952 Selman Abraham Waksman Discovery of streptomycin 1982 Sir John R.Vane Discovery of prostaglandins 1999 Alfred G.Gilman Discovery of G proteins & their role in signal transduction in cells Martin Rodbell 1999 Arvid Carlson Discovery that dopamine is neurotransmitter in the brain whose depletion leads to symptoms of Parkinson’s disease Drug nomenclature: i. Chemical name ii. Non-proprietary name iii. Proprietary (Brand) name Source of drugs: Natural – plant /animal derivatives Synthetic/semisynthetic Plant Part Drug obtained Pilocarpus microphyllus Leaflets Pilocarpine Atropa belladonna Atropine Datura stramonium Physostigma venenosum dried, ripe seed Physostigmine Ephedra vulgaris Ephedrine Digitalis lanata Digoxin Strychnos toxifera Curare group of drugs Chondrodendron tomentosum Cannabis indica (Marijuana) Various parts are used ∆9Tetrahydrocannabinol (THC) Bhang - the dried leaves Ganja - the dried female inflorescence Charas- is the dried resinous extract from the flowering tops & leaves Papaver somniferum, P album Poppy seed pod/ Capsule Natural opiates such as morphine, codeine, thebaine Cinchona bark Quinine Vinca rosea periwinkle plant Vinca alkaloids Podophyllum peltatum the mayapple
    [Show full text]
  • United States Patent (10) Patent No.: US 9,724,340 B2 Liang Et Al
    USOO9724340B2 (12) United States Patent (10) Patent No.: US 9,724,340 B2 Liang et al. (45) Date of Patent: Aug. 8, 2017 (54) ANTITUSSIVE COMPOSITIONS AND 5,952,339 A 9, 1999 Bencherif METHODS 5,969,144 A 10, 1999 London 6.432,975 B1 8, 2002 Schmitt 6,734,215 B2 5/2004 Shytle (71) Applicant: Attenua, Inc., New York, NY (US) 6,953,855 B2 10/2005 MaZurov et al. 7,115,629 B2 10/2006 Farrerons (72) Inventors: Jing Liang, New York, NY (US); Peter 7.425,561 B2 9/2008 MaZurov et al. Dicpinigaitis, Armonk, NY (US); 7,754,189 B2 7/2010 MaZurov et al. Brendan Canning, Baltimore, MD 7,767,193 B2 8, 2010 MaZurov et al. s 7.981906 B2 7, 2011 Dull et al. (US); Robert Devita, Westfield, NJ 8,084,462 B2 12/2011 MaZurov et al. (US) 8,119,659 B2 2/2012 Dullet al. 8,124,618 B2 2/2012 Mazurov et al. (73) Assignee: Attenua, Inc., New York, NY (US) 8,124,619 B2 2/2012 MaZurov et al. 8,143,272 B2 3/2012 MaZurov et al. (*) Notice: Subject to any disclaimer, the term of this 8,476,2968, 158,649 B2 4/20127/2013 MazurovBencherif et et al. al. patent is extended or adjusted under 35 8,541,446 B2 9/2013 Bencherif et al. U.S.C. 154(b) by 0 days. 8,541,447 B2 9/2013 MaZurov et al. 8,846,715 B2 9/2014 Bencherif et al. (21) Appl. No.: 15/208,266 8,901,151 B2 12/2014 Bencherif et al.
    [Show full text]
  • Mai Muuttunut Piu Miu Miui
    MAIMUUTTUNUT US009943513B1 PIU MIU MIUI (12 ) United States Patent ( 10 ) Patent No. : US 9 ,943 ,513 B1 Hughey et al. (45 ) Date of Patent: * Apr . 17 , 2018 (54 ) OPIOID ABUSE DETERRENT DOSAGE (58 ) Field of Classification Search FORMS None See application file for complete search history . (71 ) Applicant : BANNER LIFE SCIENCES LLC , High Point , NC (US ) (56 ) References Cited ( 72 ) Inventors : Justin Hughey , Asheboro , NC (US ) ; U . S . PATENT DOCUMENTS Saujanya Gosangari, Jamestown, NC (US ) ; Chue Hue Yang , Greensboro , NC 4 , 828 ,836 A 5 / 1989 Miller 4 ,861 , 598 A 8 / 1989 Oshlack (US ) 4 , 970 ,075 A 11/ 1990 Oshlack 5 ,266 ,331 A 11/ 1993 Oshlack (73 ) Assignee : BANNER LIFE SCIENCES LLC , 5 , 273 , 760 A 12 / 1993 Oshlack High Point, NC (US ) 5 , 286 ,493 A 2 / 1994 Oshlack 5 ,472 , 943 A 12 / 1995 Crain 5 , 478 , 577 A 12 / 1995 Kaiko ( * ) Notice : Subject to any disclaimer, the term of this 5 , 529 , 787 A 6 / 1996 Ayer patent is extended or adjusted under 35 5 , 549 , 912 A 8 / 1996 Kaiko U . S . C . 154 ( b ) by 0 days. 5 ,656 , 295 A 8 / 1997 Oshlack 5 ,672 , 360 A 9 / 1997 Kaiko This patent is subject to a terminal dis 5 , 702 , 725 A 12 / 1997 Chadha claimer . 5 ,914 ,131 A 6 / 1999 Ayer 5 ,958 , 452 A 9 / 1999 Oshlack ( 21) Appl . No. : 15 /285 ,837 5 , 965 , 161 A 10 / 1999 Oshlack 6 , 228 , 863 B1 5 /2001 Kaiko ( 22 ) Filed : Oct . 5 , 2016 6 , 261, 599 B1 7 / 2001 Huang Related U .
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • WHO Drug Information Vol. 03, No. 4, 1989
    WHO DRUG INFORMATION VOLUME 3 • NUMBER 4 • 1989 PROPOSED INN LIST 62 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA WHO Drug Information WHO Drug Information provides an cerned with the rational use of overview of topics relating to drug drugs. In effect, the journal seeks development and regulation that to relate regulatory activity to are of current relevance and im­ therapeutic practice. It also aims to portance, and will include the lists provide an open forum for debate. of proposed and recommended In­ Invited contributions will portray a ternational Nonproprietary Names variety of viewpoints on matters of for Pharmaceutical Substances general policy with the aim of (INN). Its contents reflect, but do stimulating discussion not only not present, WHO policies and ac­ in these columns but wherever tivities and they embrace socio­ relevant decisions on this subject economic as well as technical mat­ have to be taken. ters. WHO Drug Information is pub­ The objective is to bring issues that lished 4 times a year in English and are of primary concern to drug French. regulators and pharmaceutical manufacturers to the attention of a Annual subscription: Sw.fr. 50.— wide audience of health profes­ Airmail rate: Sw.fr. 60.— sionals and policy-makers con­ Price per copy: Sw.fr. 15.— © World Health Organization 1989 Authors alone are responsible for views expressed Publications of the World Health Organization in signed contributions. enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal The mention of specific companies or of certain Copyright Convention. For rights of reproduc­ manufacturers' products does not imply that they are tion or translation, in part or In toto, applica­ endorsed or recommended by the World Health tion should be made to: Chief, Office of Organization in preference to others of a similar na­ Publications, World Health Organization, ture which are not mentioned.
    [Show full text]